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Abstract
Background: Metabolic dysregulation is one of the hallmarks of tumor cell proliferation. Evidence indicates the
potential role of the 5′adenosine monophosphate-activated protein kinase (AMPK) and protein kinase B/Akt
signaling pathway in regulating cell proliferation, survival, and apoptosis. The present study explores the effect of
metformin HCl and the combination of α- and β-asarone on the proliferation of HepG2 cells in the presence of
high glucose levels simulating the diabetic-hepatocellular carcinoma (HCC) condition.
Results: The metformin and asarone reduced HepG2 cell viability in a dose-dependent manner and induced
morphological changes as indicated by methyl thiazolyl tetrazolium (MTT) assay. The metformin and asarone
arrested the cells at the G0/G1 phase, upregulated the expression of AMPK, and downregulated Akt expression in
high glucose conditions as identified by the flow cytometry technique. Further, the upregulated AMPK led to a
decrease in the expression of phosphoenolpyruvate carboxykinase-2 (PCK-2) and sterol regulatory element-binding
protein-1 (SREBP-1).
Conclusion: The anti-proliferative effect of metformin and asarone in the diabetic-HCC condition is mediated via
AMPK and Akt pathway.
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Background
Epidemiologic evidence suggests diabetes mellitus (DM)
as one of the potential risk factors in the progression of
hepatocellular carcinoma (HCC) [1–3]. The complex
pathophysiological relationship between HCC and DM
could be due to hyperglycemia, hyperinsulinemia, insulin
resistance, insulin-like growth factor (IGF)-1, obesity, or
chronic inflammation with overlapping cell signaling
pathways. The various signal transduction pathways are
implied in uncontrolled proliferation, mutations, inva-
sion, migration, and survival of the tumor cells [4, 5].
There are a growing number of studies that propose
the 5′adenosine monophosphate-activated protein kin-
ase (AMPK), a highly conserved heterotrimeric serine/
threonine-protein kinase, is a crucial mediator as an en-
ergy sensor in all the eukaryotic cells [6]. It plays a vital
role in maintaining cellular energy homeostasis in both
diabetes and cancer growth [7, 8]. Activation of the
AMPK signaling pathway can influence changes in the
effector’s proteins involved in the regulatory process of
energy metabolism, contributing to the pathogenesis of
cancer [9–11]. Studies indicating AMPK activation cor-
relates strongly with the reduction in cell proliferation in
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tumor cells as well as non-malignant cells. These effects
are reported to be mediated through different mecha-
nisms, including the modulation of cell cycle profile, au-
tophagy, apoptosis, de novo fatty acid synthesis, and
inhibition of protein synthesis [12, 13].
In addition to the AMPK signaling pathway, the Akt, a
serine/threonine-protein kinase, also serves as an im-
portant pathway in multiple cellular processes that link
with the increased proliferation, survival, and apoptosis
of tumor cells [14, 15]. The Akt also serves as a negative
regulator of AMPK, and studies have shown that the in-
creased expression of Akt can stimulate proliferation
through multiple downstream regulations affecting the
cell cycle [16].
There is a body of evidence suggesting that metformin
reduces tumor growth directly through the inhibition of
energy metabolism and by regulation of both AMPK-
dependent and independent signaling pathways [17–20].
On the other hand, alpha (α)- and beta (β)-asarone, the
two major active constituents in volatile oils of Acorus
calamus, showed anti-cancer effects in various cancer
cell lines [21, 22]. Our previous study showed that asar-
one treatment attenuated the progression of HCC in dia-
betic conditions in a similar manner to that achieved by
metformin [23]. The present study was aimed to under-
stand whether the anti-proliferative effect of asarone is
mediated via AMPK and Akt signaling pathway similar
to the metformin, which was used as a reference drug.
Further, we have also tried to address the possibility of
the involvement of phosphoenolpyruvate carboxykinase-
2 (PCK-2) and sterol regulatory element-binding
protein-1 (SREBP-1) with cancer cell growth.
Methods
Drugs and reagents
Alpha-asarone (Lot # S18779; Purity 98% w/w; Pub-
Chem CID: 636822) and beta-asarone (Lot # STBF-1179
V; Purity 70% w/w; PubChem CID: 5281758) was pur-
chased from Sigma-Aldrich Chemical Company, USA.
Metformin HCl (Lot No: METI-1710010; PubChem
CID: 14219) was a gift sample from Angels Pharma India
Pvt. Ltd. Hyderabad, India. Polyclonal fluorescein iso-
thiocyanate (FITC) goat anti-rabbit secondary antibody
IgG was obtained from BD Biosciences, USA (Catalog
No. 554020; Lot # 8199842). The primary rabbit poly-
clonal IgG antibodies viz., 5′adenosine monophosphate-
activated protein kinase (AMPKα1; Catalog no.
orb10076; Lot # A1227), protein kinase B (Akt; Catalog
No. orb159889; Lot # K8668), phosphoenolpyruvate
carboxykinase-2 (PCK-2; Catalog no. orb5876; Lot #
A4509), and sterol regulatory element-binding protein-1
(SREBP-1; Catalog no. orb11415; Lot # A1505) were
purchased from Biorbyt Ltd., Cambridge, UK. Dulbecco’s
modified Eagle’s medium (DMEM low and high
glucose), fetal bovine serum (FBS) heat-inactivated,
trypsin-ethylenediaminetetraacetic acid (EDTA) diges-
tion solution 1×, calcium- and magnesium-free
phosphate-buffered saline (CMF-PBS), paraformaldehyde
solution, methyl thiazolyl tetrazolium (MTT), and Triton
X-100 were purchased from HiMedia Laboratories Pvt.
Ltd., Mumbai, India. All other reagents used in this
study were of cell culture grade obtained from commer-
cial suppliers.
Cell culture conditions
The HCC cell line HepG2 (ATCC® HB-8065™) was ob-
tained and grown as recommended by the American
Type Culture Collection (ATCC), USA. HepG2 cells
were cultured in DMEM either in normoglycemic (5.5
mM) or in hyperglycemic (25 mM) glucose conditions
depending upon the experiments that contained 10%
FBS supplemented with 100 U/ml penicillin and 100 μg/
ml streptomycin (Sigma-Aldrich Chemical Company,
USA) maintained at 37 °C in an incubator (Labwit Scien-
tific Pty Ltd., Australia).
Cytotoxicity by MTT assay
The cytotoxic effect of metformin HCl, α-asarone, and
β-asarone on the HepG2 cell line was measured separ-
ately by the MTT assay [24]. Briefly, the cells were
seeded in a 96-well flat-bottom plate (Nunc™ Micro-
Well™, Thermo Fisher Scientific Inc., USA) with 200 μl
of cell suspension containing approximately 10,000 cells/
well and allowed to adhere by incubating for 24 h at
37 °C. After 24 h, the medium was discarded and re-
placed with a fresh medium (200 μl) containing different
concentrations of metformin HCl (1.6, 3.2, 6.4, 12.8, and
25.6 mM) and α- and β-asarone (0.12, 0.24, 0.48, 0.96,
and 1.92 mM) followed by incubation for another 48 h.
Untreated cells were used as control. All the media was
discarded, and 200 μl of methyl thiazolyl tetrazolium
(MTT) solution (0.5 mg/ml in phosphate-buffered saline)
was added to each well and incubated for 3 h. Further,
the MTT culture medium was removed without disturb-
ing the crystals formed and 100 μl of dimethyl sulfoxide
(DMSO) was added to each well to solubilize formed
formazan crystals. Absorbance was recorded at 570 nm
using a microplate reader (Biobase® EL-10A, China) to
calculate the percent cell viability using the following
formula:
Percent cell viability ¼ At −Abð Þ
Ac −Abð Þ  100
where At is the absorbance value of the test com-
pounds (metformin and asarone), Ab is the absorbance
value of the blank, and Ac is the absorbance value of the
control (untreated cells).
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Further, the percent of the cell viability against the
concentration of each test compound was plotted and
the inhibitory concentration 50 (IC50) value was gener-
ated from the dose-response curve.
Experimental study design
The IC50 values of metformin HCl and α- and β-asarone
were 12.87, 0.61, and 0.73 mM, respectively, and this
represents one half of the IC50 value generated from the
MTT assay (Table 1). Further, the HepG2 cells were di-
vided into four groups: the normoglycemic (NG) cul-
tured in normal glucose of 5.5 mM, the hyperglycemic
(HG) cultured in high glucose of 25 mM, the HG group
treated with metformin HCl (12.87 mM), and the HG
group treated with a combined dose of asarone (0.61
mM (α)-asarone; 0.73 mM (β)-asarone).
Cell cycle analysis
The phases of the cell cycle were analyzed by measuring
the amount of propidium iodide (PI)-labeled DNA stain-
ing in ethanol-fixed cells, as described elsewhere [25]. In
brief, HepG2 cells (5 × 105 cells/well) were seeded in a
6-well plate (Nunc™, Thermo Fisher Scientific Inc., USA)
and allowed to adhere for 24 h at 37 °C. Thereafter, fresh
DMEM medium containing 10% FBS was cultured with
NG, HG, HG + Metformin, and HG + Asarone for 16 h.
Subsequently, the trypsinized cells were fixed (70%
chilled ethanol at 4 °C for 30 min), stained with PI-
RNase solution (BD Biosciences, USA), and incubated at
room temperature in the dark for 30 min. Further, the
stained cells were collected and mixed well for analysis.
A cytomics FC500 flow cytometer (Beckman-Coulter,
USA) equipped with CXP software was used to collect
the data. The analysis of results was made by measuring
the forward scatter (FS) and side scatter (SS) for the
identification of the single cells. Further, pulse shape
processing was enabled to exclude all the clumps and
doublet cells for the analysis by using pulse area vs.
pulse width depending upon the experiment. Finally, the
data were evaluated by using an algorithm (fit Gaussian
curves) available in the FlowJo v10.0.7 software, and the
PI-stained histogram plots represent the percentage of
Table 1 The IC50 values of metformin HCl and α- and β-asarone based on the MTT assay and dose selected for further studies
Test compounds IC50 values in mM (MTT assay) One half of the IC50 in mM used for detailed studies
Metformin HCl 25.74 12.87
α-Asarone 1.22 0.61
β-Asarone 1.46 0.73
Fig. 1 Metformin and asarone inhibit the growth and modify the morphology of HepG2 cells. A–C Cells were treated with metformin HCl, α-
asarone, and β-asarone as indicated for 48 h and the cell viability was determined by MTT assay. D Representative images to show the
morphology of HepG2 cells under an inverted microscope. The scale of the bar is 100 μm. a Untreated group; the morphology of HepG2 cells
had a high density with adherent cell colonies, whereas, in the treatment group, metformin HCl (b) and asarone (c, d) at higher concentration
showed lower density with a small round body. Values represent mean ± SEM of an experiment done in triplicate; one-way ANOVA followed by
Bonferroni test, where *p < 0.05, **p < 0.01, and ***p < 0.001 compared to the untreated (UT) group
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cells in different phases of the cell cycle of an
experiment.
Expression of AMPKα1, Akt, PCK-2, and SREBP-1
The quantitative analysis of the expression of the intra-
cellular markers was performed by flow cytometry using
a 6-well plate. The cells were cultured at a density of 3 ×
105 cells/2 ml and allowed to adhere for 24 h at 37 °C.
The next day, the medium was discarded and washed
with 1000 μl of 1× phosphate-buffered saline (PBS) and
the cells were treated with metformin and asarone; if
not, they are served as a control. The drug-treated media
were removed from all the wells, transferred into a 5-ml
centrifuge tube, and washed with 500 μl PBS. The PBS
was then removed and transferred to the same centri-
fuge tube. Further, 200 μl of the trypsin-EDTA solution
was added to all the wells and incubated for 4 min at
37 °C. Finally, the cells were harvested directly into the
centrifuge tube after transferring back the medium from
the respective wells. Thereafter, the cells containing the
media were centrifuged at 300×g at 25 °C for 5 min. The
supernatant was decanted carefully, treated with 500 μl
of 2% paraformaldehyde (PFA) solution, and incubated
for 20 min at room temperature. Cells were further
mixed with 1000 μl of 1× PBS to dilute PFA solution
and centrifuged at 300×g at 25 °C for 5 min. After
decanting the supernatant, cells were permeabilized by
treatment with 500 μl of 0.1% Triton X-100, mixed well,
and incubated for another 10 min. Afterwards, cells were
mixed with 1000 μl of 0.5% BSA solution for settlement
and centrifuged at 200×g at 25 °C for 5 min and the
supernatant was decanted. Further, 0.5% BSA solution in
1× PBS was added with 6 μl of primary antibody
(AMPKα1, Akt, PCK-2, and SREBP-1) not exceeding the
final volume more than 100 μl, mixed well, and
Fig. 2 The combined cell viability activity of α + β-asarone (0.61 mM
+ 0.73 mM) was more effective than the single entity of either α- or
β-asarone (0.61 mM or 0.73 mM) when compared to the untreated
(UT) group. Values represent mean ± SEM of an experiment done in
triplicate; one-way ANOVA followed by Bonferroni test, where *p <
0.05, **p < 0.01, and ***p < 0.001 when compared as indicated
Fig. 3 Metformin and asarone block HepG2 cells in G0/G1 phase in hyperglycemic condition a Cell cycle profile of HepG2 cells cultured in normal
glucose (NG; 5.5 mM), high glucose (HG; 25 mM), HG + Metformin HCl, and HG + Asarone for 16 h and stained with PI-RNase was determined by
flow cytometry. b Bar diagrams represent the percentage (%) of cells in different phases of the cell cycle
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incubated at 25 °C for 1 h. After incubation, it was
washed with 0.5% BSA solution, resuspended with 500 μl
of 0.5% BSA in 1× PBS, and added with 6 μl of the sec-
ondary antibody and incubated. After 1 h of incubation
in a dark room at 25 °C, cells were centrifuged and dec-
anted. Finally, cells were resuspended in 500 μl of 0.5%
BSA, mixed well, and analyzed. A cytomics FC500 flow
cytometer (Beckman-Coulter, USA) equipped with CXP
software was used to collect the data. The analysis of the
results was carried out, as explained previously. The
higher the value of geometric mean fluorescence inten-
sity (GMFI), the higher the expression of individual
markers of the cells as a population.
Statistical analysis
Statistical analysis was performed using statistical soft-
ware GraphPad Prism version 6.0 (GraphPad Software,
San Diego, CA, USA). Data from the individual experi-
ments are represented as mean ± SEM and were con-
ducted in triplicate. The results obtained were analyzed
using one-way analysis of variance (ANOVA) followed
by Bonferroni multiple comparison test, and p ˂ 0.05
were considered as significant.
Results
Metformin and asarone inhibit the growth and modify
the morphology of HepG2 cells
Metformin HCl (1.6 to 25.6 mM), α-asarone (0.12 to
1.92 mM), and β-asarone (0.48 to 1.92 mM) inhibited the
cell viability of HepG2 cells in a concentration-
dependent manner compared to untreated cells (Fig. 1A-
C). The original morphology of the cells in the untreated
group had a high density with adherent cell colonies,
wherein few cells piled up, with a multilayered appear-
ance. Following treatment with metformin HCl, α-
asarone, and β-asarone, the cell morphology was charac-
terized by low density, small round bodies due to shrink-
age and the detachment of non-viable cells in a dose-
dependent manner (Fig. 1D). The results are representa-
tive of experiments performed on three different
occasions.
The combined effect of α- and β-asarone inhibits the cell
proliferation
The corresponding MTT results showed that the cell
proliferation of α- or β-asarone was inhibited compared
to the untreated cells (p < 0.01) and that the combined
effect of α- and β-asarone (0.61 mM + 0.73 mM) was
Fig. 4 The treatment of high glucose-promoted HepG2 cells with metformin and asarone downregulates the expression of PCK-2. a A
representative flow cytometry histogram events depicting the expression of PCK-2 in normal glucose (NG; 5.5 mM), high glucose (HG; 25 mM), HG
+ Metformin HCl, and HG + Asarone. b Bar diagrams represent geometric mean fluorescence intensity (GMFI) of PCK-2 in HepG2 cells. Values
represent mean ± SEM of an experiment done in triplicate; one-way ANOVA followed by Bonferroni test, where ***p < 0.001 compared to the
normal glucose (NG) group and ###p < 0.001 compared to the high glucose (HG) group
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better (p < 0.05) than the single effect of α- or β-asarone
(0.61 mM or 0.73mM) (Fig. 2).
Metformin and asarone block HepG2 cells in the G0/G1
phase in hyperglycemic condition
We observed that in HepG2 cells, the percentage of the
cells in the sub G1 phase was less in high glucose than
in normal glucose. Metformin and asarone treatment
arrested the cells in the G0/G1 phase and reduced the
cell count in S-phase cultured in high glucose concen-
tration. Further, metformin retained the cells in the sub
G1 population stage (Fig. 3a, b). These results indicate
that metformin and asarone inhibit cell proliferation at
the G0/G1 phase of the cell cycle.
Metformin and asarone inhibit the expression of PCK-2
and SREBP-1 via the AMPKα1 pathway
Based on the observation that metformin and asarone
treatment induces the cytotoxicity of HepG2 cells in
high glucose conditions, we measured whether this is a
consequence of altered cellular energy homeostasis. The
PCK-2 and SREBP-1 are the downstream regulators in
the AMPK pathway, which regulate gluconeogenesis,
glucose uptake, and de novo lipogenesis. Flow cytometry
analysis revealed that AMPKα1 expression was enhanced
by both metformin and asarone. Figures 4, 5, and 6 indi-
cate the flow cytometry histogram events and geometric
mean fluorescence intensity (GMFI) depicting the ex-
pression of respective markers in HepG2 cells. A signifi-
cant increase in the expression of AMPKα1 was
observed indicated by the increase in the GMFI for met-
formin (p < 0.01) and asarone (p < 0.001) compared with
the negative control (Fig. 6). Further, it was observed
that the expression of PCK-2 (p < 0.001; p < 0.001) and
SREBP-1 (p < 0.01; p < 0.001) decreased in the metfor-
min- and asarone-treated groups (Figs. 4 and 5).
Metformin and asarone decrease the expression of Akt
The phosphatidylinositol 3-kinase/protein kinase B
(PI3K/Akt), a prototypic signaling pathway, is increas-
ingly implicated in carcinogenesis and plays a key role in
the regulation of the growth and proliferation of cells.
The change in the glucose concentration did not have
any effect on the expression of Akt in HepG2 cells.
However, a significant decrease in the expression levels
of Akt was observed in metformin (p < 0.01) and asar-
one (p < 0.001) groups compared to untreated cells as
indicated by GMFI (Fig. 7).
Fig. 5 The treatment of high glucose-promoted HepG2 cells with metformin and asarone downregulates the expression of SREBP-1. a A
representative flow cytometry histogram events depicting the expression of SREBP-1 cultured in normal glucose (NG; 5.5 mM), high glucose (HG;
25 mM), HG + Metformin HCl, and HG + Asarone. b Bar diagrams represent geometric mean fluorescence intensity (GMFI) of SREBP-1 in HepG2
cells. Values represent mean ± SEM of an experiment done in triplicate; one-way ANOVA followed by Bonferroni test, where ##p < 0.01 and ###p <
0.001 compared to the high glucose (HG) group
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Discussion
Many experimental as well as epidemiological studies
suggest that the higher plasma glucose level might play a
crucial role in cancer development and progression [26–
29]. However, the involvement of regulatory pathways
between the effect of hyperglycemia (HG) and hepatic
cancer remains largely unexplored. In the present study,
we attempted to explore the effect of metformin and
asarone in abating the proliferation of HepG2 cells in
high glucose conditions. The results of this study suggest
that metformin and asarone suppress the hepatic cancer
cell viability and arrested the cell cycle at the G0/G1
phase by AMPK activation and Akt inhibition.
Studies, including our own, suggest that higher blood
glucose concentration may be associated with the in-
creased risk of cancers [23, 30–33]. The increased prolif-
eration of HepG2 cells at elevated glucose levels may be
due to glucose toxicity resulting from increased produc-
tion of reactive oxygen species (ROS) and alteration in
the expression of genes [4, 34]. Other work reported that
this could be due to a favorable environment for the
cancer-signaling pathway leading to proliferation, muta-
tions, invasion, migration, and survival [4]. The AMPK
and Akt signaling pathways, along with their down-
stream regulators, are indicated to play an important
role in the regulation of cancer as well as glucose metab-
olism [35].
Classically, the 5′adenosine monophosphate-activated
protein kinase (AMPK) has been identified as a central
metabolic sensor playing a significant role in energy
homeostasis. However, the emerging evidence suggests
AMPK is a possible metabolic tumor suppressor and has
been implicated in preventing and treating tumor
growth [36–38]. The AMPK activation can regulate vari-
ous tissue- and cell-specific downstream markers re-
sponsible for proliferation, autophagy, and apoptosis [12,
13, 39]. The observed anti-proliferative actions of met-
formin and asarone in a high glucose environment and
changes of AMPKα1 expression are in accordance with
many other studies that correlate with AMPK activation
and inhibition of tumor growth [9–11]. These findings
suggest that the HepG2 cell line proliferation is inversely
correlated to AMPK activity in high glucose conditions.
The evidence indicates the altered expression of gluco-
neogenic enzymes during HCC growth and differenti-
ation, in particular, the phosphoenolpyruvate
carboxykinase (PCK or PEPCK) genes. The metformin
and asarone treatment decreased the expression of PCK-
2 (a downstream regulator of AMPK), a gluconeogenic
factor in the liver that plays a role in the regulation of
Fig. 6 The treatment of high glucose-promoted HepG2 cells with metformin and asarone upregulates the expression of AMPKα1. a A
representative flow cytometry histogram events depicting the expression of AMPKα1 cultured in normal glucose (NG; 5.5 mM), high glucose (HG;
25 mM), HG + Metformin HCl, and HG + Asarone. b Bar diagrams represent geometric mean fluorescence intensity (GMFI) of AMPKα1 in HepG2
cells. Values represent mean ± SEM of an experiment done in triplicate; one-way ANOVA followed by Bonferroni test, where ##p < 0.01 and ###p <
0.001 compared to the high glucose (HG) group
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the gluconeogenesis process by catalyzing the conversion
of oxaloacetate (OAA) to phosphoenolpyruvate (PEP) [40,
41]. Elevated expression of the PCK-2 gene is found in dif-
ferent cancers and is linked to increased anabolic metabol-
ism, thereby playing a vital role in cancer cell proliferation
[42, 43]. The observed upregulation of PCK-2 expression
in our study could be due to an increase in glucose uptake
and utilization, supporting the anabolic metabolism and
promoting cell proliferation. In contrast, the expression of
PCK-2 in the metformin and asarone treatment was
downregulated, indicating the involvement of the glucose
metabolism pathway in suppressing the growth of cancer
cells. The earlier work suggested the role of PCK or
PEPCK in increasing the glutamine and glucose concen-
tration, thus linking anabolic pathways to cancer cell pro-
liferation both in vivo and in vitro [44]. Furthermore, Akt
also regulates the PCK or PEPCK expression mediated
through phosphorylation of cyclic AMP response
element-binding/Forkhead box protein O1 (CREB/
FOXO1) transcriptional activity [45].
Furthermore, both AMPK and Akt are the upstream
regulator of sterol regulatory element-binding protein-1
(SREBP-1) and can directly phosphorylate SREBP-1. Re-
cently, SREBP-1, which gets upregulated in different
types of cancer, has been linked to play a role in the
oncogenic signaling-mediated glucose uptake and de
novo lipogenesis [46–48]. The pharmacological targeting
of SREBP-1 has revealed to significantly inhibit the glio-
blastoma cell growth, suggesting it as a novel molecular
target in cancer [49]. In addition to regulation by AMPK,
SREBP-1 has shown to be activated by the Akt/PI3K
prototypic survival signaling pathway in different types
of cancer. Collectively, it demonstrated the role of the
Akt/PI3K signaling pathway via SREBP-1 integrating
lipogenesis and glucose metabolism for rapid cancer
progression [49–51]. In our study too, metformin and
asarone decreased SREBP-1 expression in a high
glucose-induced proliferation of HepG2 cells, indicating
the involvement of the AMPK/SREBP-1 or Akt/SREBP-1
signaling pathway.
The deregulation of the Akt/PI3K prototypic survival
signaling pathway also plays an important role in cell pro-
liferation. Evidence indicates that abnormal activation of
the Akt/PI3K signaling pathway frequently occurs in HCC
patients [14–16]. In this study, metformin and asarone
treatment significantly decreased the expression level of
Akt, thereby suppressing HepG2 cell proliferation. These
findings are supported by other workers who suggest that
metformin inhibited the growth of various cancer cells
through inhibition of Akt [52–54].
Fig. 7 The treatment of high glucose-promoted HepG2 cells with metformin and asarone downregulates the expression of Akt. a A
representative flow cytometry histogram events depicting the expression of Akt cultured in normal glucose (NG; 5.5 mM), high glucose (HG; 25
mM), HG + Metformin HCl, and HG + Asarone. b Bar diagrams represent geometric mean fluorescence intensity (GMFI) of Akt in HepG2 cells.
Values represent mean ± SEM of an experiment done in triplicate; one-way ANOVA followed by Bonferroni test, where ##p < 0.01 and ###p <
0.001 compared to the high glucose (HG) group
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The observed antagonistic relationship between AMPK
and Akt and their impact on the proliferation of cancer
cells is in concurrence with earlier studies by other
workers. The Akt/PI3K mediated carcinogenesis and
tumor progression gets upregulated due to the mamma-
lian target of rapamycin (mTOR) signaling pathway, which
in turn is activated due to deregulation of the AMPK [35,
55, 56]. Besides this, the deregulation of the AMPK dis-
turbs the insulin signaling pathway and results in elevated
levels of insulin-like growth factor-1/insulin, a common
pathway for both HCC and diabetic conditions [57].
Conclusion
The metformin and asarone inhibit the HepG2 cancer cell
proliferation, specifically at the G0/G1 phase of the cell cycle
in a high glucose environment, which is attributable to the
regulation of AMPK and Akt signaling pathways (Fig. 8).
Further, the inhibition of PCK-2 and SREBP-1 indicates the
link between the glucose metabolic pathway and cancer cell
growth. However, the potential limitations of the study in-
clude the possibility of adopting other molecular biological
methods to verify our findings, along with the role of specific
activators or inhibitors in high glucose-induced HepG2 cell
proliferation through modulation of both the AMPK and
Akt signaling pathways. Further, the investigation about the
possibility of involvement of multiple pathways is essential to
elucidate the molecular mechanism/s of metformin and asar-
one in controlling the progression of cancer.
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